Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours Β· Estimated delivery Oct 11 - Oct 16
The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide
Treatment recommendations, prescriptions, and all clinical decisions are made solely by licensed healthcare providers based on medical necessity, patient eligibility, applicable standards of care, and state and federal laws
The answer is, yes probably
Researchers from the National Institute on Drug Abuse, National Institutes of Health and Case Western Reserve University School of Medicine used a target trial emulation framework to evaluate the comparative effectiveness of the new use of semaglutide versus the new use of 7 other anti-diabetes medications, including other GLP-1RAs, on TUD-related health care measures in 3 study populations: patients with comorbid type 2 diabetes and TUD, patients with comorbid type 2 diabetes and TUD who had a diagnosis of obesity, and those who did not have a diagnosis of obesity
[1] [2] A 2011 Cochrane review showed a HbA1c reduction of 0.20% more with exenatide 2 mg compared to insulin glargine, exenatide 10 g twice daily, sitagliptin and pioglitazone
